Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Leap Therapeutics Inc | LPTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.20 | 04:18:56 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.20 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.235 - 10.20 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.20 | USD |
Leap Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 81.81M | 25.57M | - | 0 | -81.41M | -3.18 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Leap Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LPTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.94 | 3.33 | 2.77 | 3.05 | 175,406 | 0.26 | 8.84% |
| 1 Month | 2.50 | 4.39 | 2.42 | 3.10 | 555,594 | 0.70 | 28.00% |
| 3 Months | 2.85 | 4.39 | 2.125 | 2.99 | 327,025 | 0.35 | 12.28% |
| 6 Months | 1.46 | 5.00 | 1.3111 | 2.95 | 293,912 | 1.74 | 119.18% |
| 1 Year | 3.545 | 10.20 | 1.235 | 4.38 | 439,532 | -0.345 | -9.73% |
| 3 Years | 17.10 | 41.70 | 1.235 | 19.54 | 1,152,044 | -13.90 | -81.29% |
| 5 Years | 17.20 | 41.70 | 1.235 | 19.72 | 921,688 | -14.00 | -81.40% |
Leap Therapeutics Description
| Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205. |
